Inventors with similar research interests:
Location History:
- K.phi.benhaven .phi., DK (1997)
- K.o slashed.benhaven, DK (1997 - 1998)
- Tjele, DK (1999)
- Kobenhavn, DK (1999)
- V.ae butted.rl.o slashed.se, DK (1999)
- K.o slashed.benjavn, DK (1999)
- Copenhagen, DK (1993 - 2000)
- K.o slashed.benhavn, DK (1997 - 2000)
- K.o slashed.benhaven .O slashed., DK (1997 - 2000)
- K.o slashed.benhavn .O slashed., DK (1998 - 2000)
- Kobenhavn O, DK (2000)
- København, DK (2001 - 2003)
- Vaerloese, DK (2004)
- Kgs. Lyngby, DK (2010)
- Holte Ihsa, DK (2012)
- Lyngby, DK (2001 - 2014)
- Holte, DK (2013 - 2017)
Company Filing History:
45 out of 1,777 
9 out of 50 
3 out of 88 
Years Active: 1993-2017
Areas of Expertise:
Title: Innovations of Henrik Sune Andersen
Introduction
Henrik Sune Andersen is a renowned inventor based in Lyngby, Denmark, known for his significant contributions to the field of inflammatory disease treatment. With an impressive portfolio of 63 patents, his work has substantially impacted medical research and therapeutic advancements.
Latest Patents
Among his latest innovations are the antagonistic DR3 ligands, which are pivotal in treating inflammatory diseases. The current disclosures highlight the utility of these ligands as therapeutic agents, providing fresh avenues for the management of various inflammatory conditions.
Career Highlights
Henrik has built an illustrious career with notable organizations in the pharmaceutical industry, including Novo Nordisk A/S and High Point Pharmaceuticals, LLC. His tenure at these companies has allowed him to spearhead research and development initiatives that translate into patented innovations.
Collaborations
Throughout his career, Henrik has collaborated with esteemed colleagues such as Knud Erik Andersen and Uffe Bang Olsen. These partnerships have fostered a rich environment of knowledge exchange and innovation, resulting in groundbreaking discoveries that advance therapeutic strategies.
Conclusion
In summary, Henrik Sune Andersen exemplifies the essence of innovation in the pharmaceutical field. Through his extensive patent portfolio and collaborative efforts, he continues to push the boundaries of treatment for inflammatory diseases, making a lasting impact on both the scientific community and patient care.